Summit Corporation PLC: Summit to Present at the Canaccord Genuity 34th Annual Growth Conference

Summit Corporation PLC: Summit to Present at the Canaccord Genuity 34th Annual
                              Growth Conference

Summit Corporation plc
('Summit' or the 'Company')

SUMMIT TO PRESENT COMPANY OVERVIEW AT THE CANACCORD GENUITY 34TH ANNUAL GROWTH
CONFERENCE

Oxford, UK, 7 August 2014 - Summit (AIM: SUMM), the drug discovery and
development company advancing therapies for Duchenne Muscular Dystrophy
('DMD') and C. difficile infection ('CDI'), announces that it will be
presenting at the Canaccord Genuity 34th Annual Growth Conference on
Wednesday, August 13, 2014, at 16:00 ET (21:00 BST). The conference will be
held at the InterContinental Boston Hotel in Boston, MA.

Mr Glyn Edwards, Summit's Chief Executive Officer, will present a review of
the Company's utrophin modulation programme for the treatment of the fatal
muscle wasting disease DMD and he will also review Summit's selective
antibiotic in development for the treatment of CDI.

A copy of the presentation will be available immediately after the event on
the Investor Relations section of the Company's website, www.summitplc.com.

                                   - END -

Notes to Editors

About Summit
Summit is an Oxford, UK based drug discovery and development company targeting
high-value areas of unmet medical need including Duchenne Muscular Dystrophy
and C. difficile infection. Summit is quoted on the AIM market of the London
Stock Exchange and trades under the ticker symbol SUMM. Further information is
available at www.summitplc.com and Summit can be followed on Twitter
(@summitplc).

For more information, please contact:

Summit                               Tel: +44 (0)1235 443 939
Glyn Edwards / Richard Pye
Cairn Financial Advisers LLP         Tel: +44 (0)20 7148 7900
(Nominated Adviser)
Liam Murray / Tony Rawlinson
N+1 Singer                           Tel: +44 (0)20 7496 3000
(Broker)
Aubrey Powell / Jen Boorer
Peckwater PR                         Tel: +44 (0)7879 458 364
(Financial public relations, UK)     tarquin.edwards@peckwaterpr.co.uk
Tarquin Edwards
MacDougall Biomedical Communications Tel: +1 781-235-3060
(US media contact)                   mavery@macbiocom.com
Michelle Avery

------------------------------------------------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Summit Corporation PLC via Globenewswire
HUG#1847074
 
Press spacebar to pause and continue. Press esc to stop.